Kras G12c Mutated Locally Advanced Or Metastatic Non Small Cell Lung Cancer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for kras g12c mutated locally advanced or metastatic non small cell lung cancer. 22 active patents protecting 2 drugs from 2+ originators. First major cliff: 2038. Daily refresh.

2
Approved drugs
22
Active US patents
59/100
Avg vulnerability
$505M
Annual revenue covered

Originators in Kras G12c Mutated Locally Advanced Or Metastatic Non Small Cell Lung Cancer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Amgen 18 patents Bristol-Myers Squibb 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating kras g12c mutated locally advanced or metastatic non small cell lung cancer. Each bar = one year. Y-axis scaled to peak year (12 patents).

1
37
3
38
3
39
12
40
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lumakras
SOTORASIB
 Amgen 18 63 $300M 2038-05-21
Krazati
ADAGRASIB
 Bristol-Myers Squibb 4 54 $205M 2037-05-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12280056 Lumakras method of use 75 2039-11-18
12280056 Lumakras method of use 75 2039-11-18
12280056 Lumakras method of use 75 2039-11-18
11236091 Lumakras method of use 75 2040-05-20
11827635 Lumakras method of use 75 2040-05-20
12398133 Lumakras method of use 75 2040-05-20
12398133 Lumakras method of use 75 2040-05-20
12398133 Lumakras method of use 75 2040-05-20
11426404 Lumakras method of use 75 2040-09-15
12336995 Krazati method of use 75 2041-02-05

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10519146 Lumakras composition of matter 12 2038-05-21
10519146 Lumakras composition of matter 12 2038-05-21
12281113 Krazati composition of matter 17 2041-09-10
10519146 Lumakras composition of matter 17 2038-05-21
12383503 Krazati formulation 55 2043-08-21
11426404 Lumakras method of use 70 2040-09-15
11426404 Lumakras method of use 70 2040-09-15
11236091 Lumakras method of use 70 2040-05-20
11236091 Lumakras method of use 70 2040-05-20
11827635 Lumakras method of use 70 2040-05-20

Related